Table I.
Relative skin recovery of model biomarkers
| Biomarker | Concentration injected (pg/ml)a | Relative skin recovery (%)b |
|
|---|---|---|---|
| Mean ± SD | CV | ||
| IL-1α |
|
15.2 ± 5.1 |
33.7 |
| 233 | 15.7 ± 6.7 | 42.9 | |
| 700 | 13.9 ± 5.2 | 37.2 | |
| 2,100 |
16.2 ± 3.3 |
20.3 |
|
| IL-6 |
|
9.3 ± 2.9 |
30.9 |
| 384 | 9.9 ± 3.1 | 31.3 | |
| 960 | 7.3 ± 1.9 | 25.9 | |
|
|
2,400 |
10.6 ± 2.5 |
23.8 |
| IL-17 |
|
10.7 ± 2.6 |
24.9 |
| 560 | 10.5 ± 3.3 | 31.3 | |
| 1,400 | 10.6 ± 3.2 | 30.1 | |
|
|
3,500 |
10.9 ± 2.6 |
22.4 |
| TNF-α |
|
6.5 ± 2.7 |
40.9 |
| 561 | 5.4 ± 3.5 | 66.0 | |
| 1,404 | 6.4 ± 2.0 | 31.6 | |
| 3,510 | 7.9 ± 1.6 | 19.7 | |
a
Reference solutions of interleukin (IL)-1α, IL-6, IL-17 and tumour necrosis factor (TNF)-α injected into thawed skin specimens before sampling.
b
Mean relative skin recovery is based on data obtained from triplicate probes, which were used for every biomarker concentration and repeated in skin specimens from 3 donors (D4, D18, and D20).
SD: standard deviation; CV: coefficient of variation.